HPR Stock Overview Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Horizon Therapeutics Public Limited Company Competitors Price History & Performance
Summary of share price highs, lows and changes for Horizon Therapeutics Historical stock prices Current Share Price US$110.20 52 Week High US$110.80 52 Week Low US$61.68 Beta 1.01 1 Month Change 3.38% 3 Month Change 17.86% 1 Year Change 67.30% 3 Year Change 54.28% 5 Year Change 601.91% Change since IPO 1,783.76%
Recent News & Updates
Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders Jan 17
Horizon Therapeutics Public Limited Company Files Form 15 Oct 17
Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP). Oct 08 Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP). Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index
Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes Oct 01 See more updates
Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders Jan 17
Horizon Therapeutics Public Limited Company Files Form 15 Oct 17
Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP). Oct 08 Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP). Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index
Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes Oct 01
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata Sep 14
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition Sep 03 Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition Sep 02
Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023 Jul 18 Horizon Therapeutics plc Announces New Analysis of MRI Findings Shows UPLIZNA®? (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People with Neuromyelitis Optica Spectrum Disorder
Horizon Therapeutics plc Announces Tepezza® (Teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease Jun 28
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (Optic-J) in Japan Jun 23 Horizon Therapeutics plc Announces Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration
Horizon Therapeutics plc Announces the Publication of New Analysis from the N-MOmentum Clinical Trial of UPLIZNA Demonstrating the Utility of A Robust Assay Process Jun 13
Horizon Therapeutics plc Announces Data from the Teprotumumab Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease Jun 06
Horizon Therapeutics plc Announces the Publication of New Data from the Phase 3 N-MOmentum Pivotal Trial of UPLIZNA Jun 02
Horizon Therapeutics plc Announces Presentations At the 2023 Eular European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’S Syndrome Jun 01
Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023 Jan 31
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population Jan 19
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus Jan 05 Amgen Inc. (NasdaqGS:AMGN) entered into a transaction agreement to acquire Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) for $27.1 billion. Dec 14
Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout Dec 10
Investor sentiment improved over the past week Dec 01
Insufficient new directors Nov 23
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (Optic-J) in Japan Evaluating Tepezza® for the Treatment of Active Thyroid Eye Disease Nov 17
Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection Nov 10
Investor sentiment improved over the past week Nov 09
Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection Nov 09
Horizon Therapeutics Public Limited Company Announces Data Support the Use of KRYSTEXXA (Pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People with Mild-To-Moderate Chronic Kidney Disease Nov 08
Third quarter 2022 earnings released: EPS: US$0.59 (vs US$1.44 in 3Q 2021) Nov 03
Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022 Nov 03
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis Oct 28
Horizon Therapeutics plc Announces New Data from Two Analyses of the Uplizna Phase 3 Pivotal Trial Presented At the 38(Th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims 2022), Oct. 26-28 in Amsterdam Oct 27
Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022 Oct 07
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (Teprotumumab-Trbw) in Adults with Chronic/Low Clinical Activity Score (Cas) Thyroid Eye Disease (Ted) Sep 30
Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology Sep 15
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint Sep 13 Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) announces an Equity Buyback for $500 million worth of its shares. Sep 10
Second quarter 2022 earnings released: EPS: US$0.27 (vs US$0.70 in 2Q 2021) Aug 04 Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy Jul 09
Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022 Jul 08
Horizon Therapeutics Public Limited Company Announces New Analysis Finds UPLIZNA (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD) Jun 25
Horizon Therapeutics plc Submits Regulatory Filing for Uplizna® (Inebilizumab) in Brazil Jun 16
Horizon Therapeutics Public Limited Company Announces Results of A New Analysis Examining Rates of Hyperglycemia Among Patients Treated with TEPEZZA for TED Compare to Placebo in the Phase 2 and OPTIC Phase 3 Clinical Trials Jun 13
Horizon Therapeutics plc Announces Analysis from the Phase 3 N-Momentum Study Demonstrates the Effectiveness of Uplizna(R) (Inebilizumab-Cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations Jun 01
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (Hzn-7734) for the Treatment of Alopecia Areata May 18
First quarter 2022 earnings released: EPS: US$0.89 (vs US$0.55 loss in 1Q 2021) May 05 Horizon Therapeutics Public Limited Company Provides Earnings Guidance for the Full Year 2022
Horizon Therapeutics plc Receives European Commission Approval of Uplizna (Inebilizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder May 04
Insufficient new directors Apr 29
Horizon Therapeutics Public Limited Company to Report Q1, 2022 Results on May 04, 2022 Apr 15
Horizon Therapeutics plc Announces Presentation of A Post-Hoc Analysis from the N-Momentum Phase 3 Pivotal Trial of UPLIZNA Apr 01
Insider recently sold €3.1m worth of stock Mar 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 03
Horizon Therapeutics plc Provides Earnings Guidance for the Full Year 2022 Mar 03
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED) Feb 24 Horizon Therapeutics plc Appoints Sean Clayton Executive Vice President
Horizon Therapeutics Public Limited Company Announces Results from a New Post-Marketing Safety Analysis of Hearing Events Associated with Tepezza for the Treatment of Thyroid Eye Disease Feb 16 Shareholder Returns HPR DE Biotechs DE Market 7D -0.2% 3.1% 0.5% 1Y 67.3% -13.8% 7.2%
See full shareholder returns
Return vs Market: HPR exceeded the German Market which returned 5.9% over the past year.
Price Volatility Is HPR's price volatile compared to industry and market? HPR volatility HPR Average Weekly Movement 2.8% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: HPR has not had significant price volatility in the past 3 months.
Volatility Over Time: HPR's weekly volatility (3%) has been stable over the past year.
About the Company Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use.
Show more Horizon Therapeutics Public Limited Company Fundamentals Summary How do Horizon Therapeutics's earnings and revenue compare to its market cap? HPR fundamental statistics Market cap €25.30b Earnings (TTM ) €416.06m Revenue (TTM ) €3.46b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HPR income statement (TTM ) Revenue US$3.64b Cost of Revenue US$824.98m Gross Profit US$2.82b Other Expenses US$2.38b Earnings US$438.00m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) 1.91 Gross Margin 77.36% Net Profit Margin 12.02% Debt/Equity Ratio 48.2%
How did HPR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/10/09 11:54 End of Day Share Price 2023/10/05 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Horizon Therapeutics Public Limited Company is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Donald Ellis Avondale Partners Gary Nachman BMO Capital Markets Equity Research Jason Matthew Gerberry BofA Global Research
Show 21 more analysts 
